Generic drug-maker wants to boost production at Columbus plant

The Columbus generic drug-making plant and lab of Hikma Pharmaceuticals PLC still has capacity for greater volume even after absorbing work from a shuttered factory in New Jersey, executives said after better-than-expected financial performance companywide in the first half of 2018. Sales of generic drugs, about a third of the London, England, company's portfolio, were $338 million in the first six months, up 11 percent from the same time last year. Most of those are developed and made at the former…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news